SCOTTSDALE, Ariz.–(BUSINESS WIRE) – Electromedical Technologies, Inc. (OTC: ELCQ) (the “Company”), a pioneer in the development and manufacturing of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that it has completed a collaborative agreement with Nazarbayev University, Nur-Sultan, Kazakhstan, to develop a comprehensive research program in defining the effects of electro-modulation on a physiological state of human body by studying the impacts of alternating electrical fields on cell signaling. There is also an interest to expand the electro-modulation studies to identify most effective frequencies interfering with replication and assembly of large single-stranded RNA viruses.
Matthew Wolfson, Founder and CEO of Electromedical Technologies, commented, “We want to create a variety of laboratory conditions where we can test virus responses, hoping that the virus can be inactivated or at the least minimize its pathogenic capacity.” These will all be non-human preliminary studies, none of which are currently cleared applications for our devices in the US.
Commenting further, Mr. Wolfson said, “More research is needed right away on this very important topic, especially now. If a vaccine is not available for a viral illness, treatment options are extremely limited today. This is why thinking outside of the box and exploring innovative ways, such as possibly using physics to inactivate viruses, is necessary and we are excited to work together with Nazarbayev University to find a potential solution.”
Dr. Dos Sarbassov, Professor of the Department of Biology, School of Sciences and Humanities at Nazarbayev University, commented, “Our preliminary non-human studies have shown promising results, indicating a substantial impact of alternating electrical fields on cell signaling that has a potential to modify a variety of physiological responses including immune system. Further studies in laboratory and in animal models will be instrumental to develop potent non-invasive electro-modulation treatments for different fields of medicine and human well-being.”
Commenting further, Dr. Sarbassov said, “However, given today’s worldwide crisis, it will be important to explore these effects on coronavirus replication. Every virus has unique molecular structure and mechanisms of propagation. Among single-stranded RNA viruses, coronaviruses are distinguished by their enormous genome size (about 30,000 bases that are at least 3 times larger than HIV genome) and by large viral protein spikes. The unconventional and innovative research will create a new scientific paradigm in understanding how a virus can be affected by vibrational motions of electrons driven by alternating electrical fields.”
A published article “Why It’s Time to Take Electrified Medicine Seriously” by Time Magazine observed: “The remarkable convergence of advances in bioengineering and neurology has resulted in a fast-developing way to treat chronic diseases, known as bioelectronic medicine. These advances allow scientists to identify specific nerves and implant devices that can be activated when needed to stimulate or dial down their activity; that in turn controls cells in organs targeted by those nerves that regulate the body’s many immune and metabolic responses.”
Safe Harbor Statement:
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.